Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2014 | -1.11 Million USD | 33.45% |
| 2013 | -1.58 Million USD | 17.79% |
| 2012 | -2.04 Million USD | -151.71% |
| 2011 | -3.59 Million USD | 258.62% |
| 2010 | -2.48 Million USD | 38.62% |
| 2009 | -4.05 Million USD | 8.8% |
| 2008 | -4.43 Million USD | 17.05% |
| 2007 | -5.22 Million USD | -18.89% |
| 2006 | -4.43 Million USD | -87.71% |
| 2005 | -2.4 Million USD | 5.99% |
| 2004 | -2.29 Million USD | -13.57% |
| 2003 | -2.24 Million USD | -69.28% |
| 2002 | -1.32 Million USD | -15.28% |
| 2001 | -1.02 Million USD | -8.68% |
| 2000 | -1.01 Million USD | 53.55% |
| 1999 | -2.23 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2015 Q2 | -143 Thousand USD | 29.56% |
| 2015 Q1 | -203 Thousand USD | 6.88% |
| 2015 Q3 | -208 Thousand USD | -45.45% |
| 2014 Q3 | -212 Thousand USD | 19.7% |
| 2014 FY | - USD | 33.45% |
| 2014 Q2 | -264 Thousand USD | 37.44% |
| 2014 Q4 | -218 Thousand USD | -2.83% |
| 2014 Q1 | -422 Thousand USD | -3.69% |
| 2013 Q3 | -319 Thousand USD | 23.13% |
| 2013 Q4 | -407 Thousand USD | -27.59% |
| 2013 Q1 | -536 Thousand USD | -12.61% |
| 2013 Q2 | -415 Thousand USD | 22.57% |
| 2013 FY | - USD | 17.79% |
| 2012 Q2 | -608 Thousand USD | -12.38% |
| 2012 Q4 | -476 Thousand USD | -14.7% |
| 2012 FY | - USD | -151.71% |
| 2012 Q1 | -541 Thousand USD | -107.69% |
| 2012 Q3 | -415 Thousand USD | 31.74% |
| 2011 Q3 | -2 Million USD | -632.48% |
| 2011 Q2 | -274 Thousand USD | 33.17% |
| 2011 Q1 | -410 Thousand USD | 14.41% |
| 2011 FY | - USD | 258.62% |
| 2011 Q4 | 7.03 Million USD | 450.32% |
| 2010 Q3 | -595 Thousand USD | 0.0% |
| 2010 Q1 | -817 Thousand USD | 2.51% |
| 2010 Q2 | -595 Thousand USD | 27.17% |
| 2010 Q4 | -479 Thousand USD | 19.5% |
| 2010 FY | - USD | 38.62% |
| 2009 Q1 | -986 Thousand USD | -1.54% |
| 2009 Q3 | -1.06 Million USD | 8.92% |
| 2009 FY | - USD | 8.8% |
| 2009 Q4 | -838 Thousand USD | 21.09% |
| 2009 Q2 | -1.16 Million USD | -18.26% |
| 2008 Q1 | -1.46 Million USD | -26.86% |
| 2008 Q4 | -971 Thousand USD | 2.51% |
| 2008 FY | - USD | 17.05% |
| 2008 Q3 | -996 Thousand USD | 0.1% |
| 2008 Q2 | -997 Thousand USD | 32.13% |
| 2007 Q4 | -1.15 Million USD | 11.47% |
| 2007 FY | - USD | -18.89% |
| 2007 Q1 | -1.22 Million USD | -27.75% |
| 2007 Q2 | -1.66 Million USD | -35.23% |
| 2007 Q3 | -1.3 Million USD | 21.3% |
| 2006 Q3 | -767 Thousand USD | 58.36% |
| 2006 Q4 | -962 Thousand USD | -25.42% |
| 2006 FY | - USD | -87.71% |
| 2006 Q2 | -1.84 Million USD | -97.22% |
| 2006 Q1 | -934 Thousand USD | -57.5% |
| 2005 Q2 | -616 Thousand USD | -24.44% |
| 2005 Q3 | -659 Thousand USD | -6.98% |
| 2005 Q4 | -593 Thousand USD | 10.02% |
| 2005 Q1 | -495 Thousand USD | 17.09% |
| 2005 FY | - USD | 5.99% |
| 2004 Q4 | -597 Thousand USD | 5.54% |
| 2004 Q2 | -580 Thousand USD | 22.04% |
| 2004 Q1 | -744 Thousand USD | -17.54% |
| 2004 FY | - USD | -13.57% |
| 2004 Q3 | -632 Thousand USD | -8.97% |
| 2003 Q1 | -585 Thousand USD | 15.74% |
| 2003 FY | - USD | -69.28% |
| 2003 Q4 | -385 Thousand USD | -115.31% |
| 2003 Q3 | -294 Thousand USD | 61.01% |
| 2003 Q2 | -754 Thousand USD | -26.94% |
| 2002 Q1 | -133 Thousand USD | -32.04% |
| 2002 FY | - USD | -15.28% |
| 2002 Q2 | -195 Thousand USD | 18.41% |
| 2002 Q4 | -705 Thousand USD | -275.0% |
| 2002 Q3 | -249 Thousand USD | 3.59% |
| 2001 Q4 | -167 Thousand USD | -33.09% |
| 2001 Q3 | -118 Thousand USD | 66.42% |
| 2001 Q2 | -396 Thousand USD | -19.12% |
| 2001 Q1 | -332 Thousand USD | -26.87% |
| 2001 FY | - USD | -8.68% |
| 2000 Q4 | -256 Thousand USD | -71.79% |
| 2000 Q1 | -313 Thousand USD | 0.0% |
| 2000 Q3 | -147 Thousand USD | 49.84% |
| 2000 Q2 | -299 Thousand USD | 3.72% |
| 2000 FY | - USD | 53.55% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.429% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 81.177% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.26% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 93.575% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.187% |
| Mesoblast Limited | -62.38 Million USD | 98.211% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 27.346% |
| Genus plc | 73.7 Million USD | 101.514% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 83.12% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 68.537% |
| Marizyme, Inc. | -34.28 Million USD | 96.745% |
| ContraFect Corporation | -64.99 Million USD | 98.283% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 87.278% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 75.344% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 20.389% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 57.798% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 51.976% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -115.425% |
| Accustem Sciences Inc. | -3.74 Million USD | 70.212% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.686% |
| EV Biologics, Inc. | -1.26 Million USD | 11.927% |
| Q BioMed Inc. | -617.62 Thousand USD | -80.691% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 131.243% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -76.469% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 51.149% |
| Biomind Labs Inc. | -1.03 Million USD | -7.873% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 111.299% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 84.416% |
| Skye Bioscience, Inc. | -13.54 Million USD | 91.762% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 24.97% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4364.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 71.269% |
| IMV Inc. | -35.52 Million USD | 96.858% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.968% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 55.395% |
| GB Sciences, Inc. | -1.41 Million USD | 21.402% |
| Alpha Cognition Inc. | -9.7 Million USD | 88.501% |
| HST Global, Inc. | -5303.00 USD | -20944.692% |
| CSL Limited | 4.78 Billion USD | 100.023% |
| Halberd Corporation | -74.27 Thousand USD | -1402.443% |
| Enzolytics Inc. | -2.12 Million USD | 47.409% |
| Resverlogix Corp. | -11.74 Million USD | 90.496% |
| Affymax, Inc. | -14.29 Million USD | 92.193% |
| SYBLEU INC | -141.57 Thousand USD | -688.297% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 63.565% |
| argenx SE | -216.02 Million USD | 99.483% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.983% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 191.701% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 25.546% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 394.58% |
| AVAX Technologies, Inc. | -6.11 Million USD | 81.743% |
| Zenith Capital Corp. | -8.6 Million USD | 87.032% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.551% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -6306.062% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 54.383% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -534.003% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.184% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 61.415% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -6.66% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 16697.264% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 36.229% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 41.903% |
| BioStem Technologies, Inc. | -7.55 Million USD | 85.226% |
| ONE Bio Corp. | 13.61 Million USD | 108.198% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -516.275% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 45.746% |
| Agentix Corp. | -1.37 Million USD | 18.644% |
| LadRx Corporation | 412.28 Thousand USD | 370.688% |
| Cell Source, Inc. | -4.27 Million USD | 73.88% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -203.904% |
| Regen BioPharma, Inc. | 1.46 Million USD | 176.128% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -19.11% |
| NovAccess Global Inc. | -1.03 Million USD | -7.847% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 112.605% |
| Itoco Inc. | -1.86 Million USD | 40.289% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -193.978% |
| Kadimastem Ltd | -2.62 Million USD | 57.476% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -366.653% |
| CytoDyn Inc. | -18.02 Million USD | 93.81% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1312.14% |
| Mobile Lads Corp. | -2.24 Million USD | 50.204% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -9025.848% |
| Qrons Inc. | -40.08 Thousand USD | -2684.362% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -129.782% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 311.591% |
| Rebus Holdings, Inc. | -951 Thousand USD | -17.35% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5.084% |
| International Stem Cell Corporation | 202 Thousand USD | 652.475% |
| Bioxytran, Inc. | -3.82 Million USD | 70.786% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2020.061% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 54.67% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.889% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2380.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 59.24% |
| Neutra Corp. | -181.24 Thousand USD | -515.734% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 94.464% |
| PureTech Health plc | -11.62 Million USD | 90.402% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 94.464% |
| IXICO plc | -707 Thousand USD | -57.85% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 85.478% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.692% |
| CSL Limited | 4.73 Billion USD | 100.024% |
| Cellectis S.A. | -92.63 Million USD | 98.795% |